Biodel: Upside from Potential Linjeta Approval
Rockford Coscia submits: I wanted to weigh in on the Biodel (BIOD) PDUFA for their rapid-acting insulin formulation, Linjeta. Many investigations have taken place here, here, and here (and my first article offered a play that has returned over 50% since July here), but I thought it would be worthwhile to provide a summary of [...]
